
What’s new in breast cancer research? – July-August 2025
Breast cancer is the second cancer-related cause of death in women worldwide, therefore it is no
Breast cancer is the second cancer-related cause of death in women worldwide, therefore it is no
Introduction Microphysiological systems (MPS) are fast becoming a cornerstone of FDA-aligned non-clinical strategy, especially when paired
Introduction Organoid and artificial intelligence approaches are central to the FDA’s roadmap for reducing animal use
Introduction Adipose tissue-breast cancer crosstalk is emerging as a key driver of tumor initiation, progression, and
Introduction Following our articles on how breast cancer organoids and breast‑cancer‑on‑chip platforms expand beyond conventional 2D and
3D breast cancer models are rapidly redefining how we investigate the world’s deadliest malignancy in women,
Breast cancer has long been one of the most prevalent and challenging cancers worldwide, demanding constant
Breast cancer remains the most frequently diagnosed malignancy in women worldwide and a leading cause of
Obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD) remain major global health concerns, yet
Adipose tissue organoid technology is reshaping metabolic research. From scaffold-free spheroids to hydrogel-based 3D adipose tissue
14 rue de la Beaune,
93100 Montreuil (Paris)
France
+33 9 87 04 70 35
contact@cherrybiotech.com
All right reserved to © Cherry Biotech 2023